Justin Klein

Justin Klein, MD, JD, is a co-founder and Managing Partner at Vensana Capital, a leading venture capital and growth equity firm dedicated to medtech innovation. Justin was previously a partner and leader of the medical technology investing practice at NEA and worked at the Duke University Health System in strategy, operations, and finance. Justin currently or previously served on the board of directors of Apella, Cartiva (acquired), ChromaCode, Cleerly, Curate Biosciences, CV Ingenuity (acquired), Epix Therapeutics (acquired), FIRE1, Intact Vascular (acquired), Metavention, Personal Genome Diagnostics (acquired), PhaseBio Pharmaceuticals (IPO), Plexium, Relievant Medsystems, Senseonics (IPO), Topera (acquired), Ulthera (acquired), Vertiflex (acquired), Vesper Medical (acquired), and VytronUS (acquired).